Fascin1 in carcinomas: Its regulation and prognostic value

International Journal of Cancer

Volumn 137, Issue 11, 2015, Pages 2534-2544

  Ma, Yafeng ^a,b   Machesky, Laura M ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

carcinomas; fascin1; prognostic marker

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FASCIN1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 145; NEUROTROPHIN RECEPTOR P75; PROTEIN KINASE C; STAT PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CELL HYPOXIA; CELL INVASION; CELL MIGRATION; COLORECTAL CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; WNT SIGNALING PATHWAY; ANIMAL; CARCINOMA; CELL MOTION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR INVASION;

ANIMALS; CARCINOMA; CELL MOVEMENT; HUMANS; MICROFILAMENT PROTEINS; NEOPLASM INVASIVENESS; PROGNOSIS;

EID: 84941655129     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29260     Document Type: Article

References (118)

1. Otto JJ, Kane RE, Bryan J,. Formation of filopodia in coelomocytes: localization of fascin, a 58,000 dalton actin cross-linking protein. Cell 1979; 17: 285-93.
2. Jayo A, Parsons M,. Fascin: a key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol 2010; 42: 1614-7.
3. Deinhardt K, Kim T, Spellman DS, et al., Neuronal growth cone retraction relies on proneurotrophin receptor signaling through Rac. Sci Signal 2011; 4: ra82.
4. Nagel J, Delandre C, Zhang Y, et al., Fascin controls neuronal class-specific dendrite arbor morphology. Development 2012; 139: 2999-3009.
5. Ma Y, Reynolds LE, Li A, et al., Fascin 1 is dispensable for developmental and tumour angiogenesis. Biol Open 2013; 2: 1187-91.
6. Adams JC, Kureishy N, Taylor AL,. A role for syndecan-1 in coupling fascin spike formation by thrombospondin-1. J Cell Biol 2001; 152: 1169-82.
7. Quintavalle M, Elia L, Condorelli G, et al., MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol 2010; 189: 13-22.
8. Yamashiro S,. Functions of fascin in dendritic cells. Crit Rev Immunol 2012; 32: 11-21.
9. Sonego M, Gajendra S, Parsons M, et al., Fascin regulates the migration of subventricular zone-derived neuroblasts in the postnatal brain. J Neurosci 2013; 33: 12171-85.
10. Ma Y, Li A, Faller WJ, et al., Fascin 1 is transiently expressed in mouse melanoblasts during development and promotes migration and proliferation. Development 2013; 140: 2203-11.
11. Machesky LM, Li A,. Fascin: invasive filopodia promoting metastasis. Commun Integr Biol 2010; 3: 263-70.
12. Zhang FR, Tao LH, Shen ZY, et al., Fascin expression in human embryonic, fetal, and normal adult tissue. J Histochem Cytochem 2008; 56: 193-9.
13. Adams JC,. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 2004; 16: 590-6.
14. Adams JC, Clelland JD, Collett GDM, et al., Cell-matrix adhesions differentially regulate fascin phosphorylation. Mol Biol Cell 1999; 10: 4177-90.
15. Shonukan O, Bagayogo I, McCrea P, et al., Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin. Oncogene 2003; 22: 3616-23.
16. Yamashiro-Matsumura S, Matsumura F,. Intracellular localization of the 55-kD actin-bundling protein in cultured cells: spatial relationships with actin, alpha-actinin, tropomyosin, and fimbrin. J Cell Biol 1986; 103: 631-40.
17. Elkhatib N, Neu MB, Zensen C, et al., Fascin plays a role in stress fiber organization and focal adhesion disassembly. Curr Biol 2014; 24: 1492-9.
18. Aratyn YS, Schaus TE, Taylor EW, et al., Intrinsic dynamic behavior of fascin in filopodia. Mol Biol Cell 2007; 18: 3928-40.
19. Li A, Dawson JC, Forero-Vargas M, et al., The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol 2010; 20: 339-45.
20. Schoumacher M, Goldman RD, Louvard D, et al., Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol 2010; 189: 541-56.
21. Winkelman JD, Bilancia CG, Peifer M, et al., Ena/VASP enabled is a highly processive actin polymerase tailored to self-assemble parallel-bundled F-actin networks with Fascin. Proc Natl Acad Sci USA 2014; 111: 4121-6.
22. Jaiswal R, Breitsprecher D, Collins A, et al., The formin Daam1 and fascin directly collaborate to promote filopodia formation. Curr Biol 2013; 23: 1373-9.
23. Wang Y, Zhou BP,. Epithelial-mesenchymal transition - A hallmark of breast cancer metastasis. Cancer Hallm 2013; 1: 38-49.
24. Keshamouni VG, Jagtap P, Michailidis G, et al., Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition. J Proteome Res 2009; 8: 35-47.
25. Li A, Morton JP, Ma Y, et al., Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology 2014; 146: 1386-96.
26. Ksiazkiewicz M, Markiewicz A, Zaczek AJ,. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 2012; 79: 195-208.
27. Kim MY, Oskarsson T, Acharyya S, et al., Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-26.
28. Xing P, Li J-G, Jin F, et al., Fascin, an actin-bundling protein, promotes breast cancer progression in vitro. Cell Biochem Funct 2011; 29: 303-10.
29. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG,. Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis. Cell Res 2007; 17: 324-32.
30. Hashimoto Y, Loftis DW, Adams JC,. Fascin-1 promoter activity is regulated by CREB and the aryl hydrocarbon receptor in human carcinoma cells. PLoS One 2009; 4: e5130.
31. Li D, Jin L, Alesi GN, et al., The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. J Biol Chem 2013; 288: 32528-38.
32. Megiorni F, Indovina P, Mora B, et al., Minor expression of fascin-1 gene (FSCN1) in NTera2 cells depleted of CREB-binding protein. Neurosci Lett 2005; 381: 169-74.
33. Clevers H,. Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469-80.
34. Kim SJ, Choi IJ, Cheong TC, et al., Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 2010; 138: 1035-45.e1-2.
35. Grothey A, Hashizume R, Ji H, et al., C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 2000; 19: 4864-75.
36. Vignjevic D, Schoumacher M, Gavert N, et al., Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res 2007; 67: 6844-53.
37. Hölsken A, Buchfelder M, Fahlbusch R, et al., Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling. Acta Neuropathol 2010; 119: 631-9.
38. Grivennikov SI, Karin M,. Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21: 11-9.
39. Snyder M, Huang XY, Zhang JJ,. Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. J Biol Chem 2011; 286: 38886-93.
40. Yao J, Qian CJ, Ye B, et al., Signal transducer and activator of transcription 3 signaling upregulates fascin via nuclear factor-kappaB in gastric cancer: implications in cell invasion and migration. Oncol Lett 2014; 7: 902-8.
41. Banno K, Yanokura M, Iida M,. Application of microRNA in diagnosis and treatment of ovarian cancer. Biomed Res Int 2014; 2014: 232817.
42. Hung CH, Chiu YC, Chen CH, et al., MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int 2014; 2014: 486407.
43. Shah NR, Chen H,. MicroRNAs in pathogenesis of breast cancer: implications in diagnosis and treatment. World J Clin Oncol 2014; 5: 48-60.
44. Browne G, Taipaleenmaki H, Stein GS, et al., MicroRNAs in the control of metastatic bone disease. Trends Endocrinol Metab 2014; 25: 320-7.
45. Courthod G, Franco P, Palermo L, et al., The role of microRNA in head and neck cancer: current knowledge and perspectives. Molecules 2014; 19: 5704-16.
46. Diaz-Lopez A, Moreno-Bueno G, Cano A,. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag Res 2014; 6: 205-16.
47. Hao J, Zhang Y, Deng M, et al., MicroRNA control of epithelial-mesenchymal transition in cancer stem cells. Int J Cancer 2014; 135: 1019-27.
48. Chiyomaru T, Enokida H, Tatarano S, et al., miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102: 883-91.
49. Kano M, Seki N, Kikkawa N, et al., miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010; 127: 2804-14.
50. Liu R, Liao J, Yang M, et al., The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One 2012; 7: e33987.
51. Fuse M, Nohata N, Kojima S, et al., Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 2011; 38: 1093-101.
52. Dynoodt P, Speeckaert R, De Wever O, et al., miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Oncol 2013; 42: 1443-51.
53. Feng Y, Zhu J, Ou C, et al., MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. Br J Cancer 2014; 110: 2300-9.
54. Gotte M, Mohr C, Koo CY, et al., miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010; 29: 6569-80.
55. Kim SJ, Oh JS, Shin JY, et al., Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 2011; 155: 427-34.
56. Kunz M, Ibrahim SM,. Molecular responses to hypoxia in tumor cells. Mol Cancer 2003; 2: 23.
57. Zeng W, Liu P, Pan W, et al., Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett 2014. doi: 10.1016/j.canlet.2014.01.032.
58. Zhao X, Gao S, Ren H, et al., Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res 2014; 74: 2455-64.
59. Conacci-Sorrell M, Ngouenet C, Anderson S, et al., Stress-induced cleavage of Myc promotes cancer cell survival. Genes Dev 2014; 28: 689-707.
60. Yamakita Y, Ono S, Matsumura F, et al., Phosphorylation of human fascin inhibits its actin binding and bundling activities. J Biol Chem 1996; 271: 12632-8.
61. Ono S, Yamakita Y, Yamashiro S, et al., Identification of an actin binding region and a protein kinase C phosphorylation site on human fascin. J Biol Chem 1997; 272: 2527-33.
62. Parsons M, Adams JC,. Rac regulates the interaction of fascin with protein kinase C in cell migration. J Cell Sci 2008; 121: 2805-13.
63. Hashimoto Y, Parsons M, Adams JC,. Dual actin-bundling and protein kinase C-binding activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis. Mol Biol Cell 2007; 18: 4591-602.
64. Molloy NH, Read DE, Gorman AM,. Nerve growth factor in cancer cell death and survival. Cancers (Basel) 2011; 3: 510-30.
65. Tsai WC, Chao YC, Sheu LF, et al., Overexpression of fascin-1 in advanced colorectal adenocarcinoma: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 2007; 23: 153-60.
66. Puppa G, Maisonneuve P, Sonzogni A, et al., Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer 2007; 96: 1118-26.
67. Ozerhan IH, Ersoz N, Onguru O, et al., Fascin expression in colorectal carcinomas. Clinics (Sao Paulo) 2010; 65: 157-64.
68. Hashimoto Y, Skacel M, Lavery I, et al., Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer 2006; 6: 241.
69. Chan C, Jankova L, Fung CL, et al., Fascin expression predicts survival after potentially curative resection of node-positive colon cancer. Am J Surg Pathol 2010; 34: 656-66.
70. Oh SY, Kim YB, Suh KW, et al., Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer. J Surg Res 2012; 172: 102-8.
71. Jung EJ, Lee JH, Min BW, et al., Clinicopathologic significance of fascin, extracellular matrix metalloproteinase inducer, and ezrin expressions in colorectal adenocarcinoma. Indian J Pathol Microbiol 2011; 54: 32-6.
72. Tsai WC, Lin CK, Lee HS, et al., The correlation of cortactin and fascin-1 expression with clinicopathological parameters in pancreatic and ampulla of Vater adenocarcinoma. APMIS 2013; 121: 171-81.
73. Yamaguchi H, Inoue T, Eguchi T, et al., Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade. Mod Pathol 2007; 20: 552-61.
74. Tsai WC, Chao YC, Sheu LF, et al., EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people. APMIS 2007; 115: 929-38.
75. Maitra A, Adsay NV, Argani P, et al., Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003; 16: 902-12.
76. Swierczynski SL, Maitra A, Abraham SC, et al., Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 2004; 35: 357-66.
77. Yoder BJ, Tso E, Skacel M, et al., The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 2005; 11: 186-92.
78. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al., Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006; 12: 1533-9.
79. Esnakula AK, Ricks-Santi L, Kwagyan J, et al., Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women. J Clin Pathol 2014; 67: 153-60.
80. Al-Alwan M, Olabi S, Ghebeh H, et al., Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One 2011; 6: e27339.
81. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, et al., Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008; 68: 989-97.
82. Takikita M, Hu N, Shou JZ, et al., Fascin and CK4 as biomarkers for esophageal squamous cell carcinoma. Anticancer Res 2011; 31: 945-52.
83. Hsu KF, Lin CK, Yu CP, et al., Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis Esophagus 2009; 22: 402-8.
84. Zhang H, Xu L, Xiao D, et al., Fascin is a potential biomarker for early-stage oesophageal squamous cell carcinoma. J Clin Pathol 2006; 59: 958-64.
85. Hashimoto Y, Ito T, Inoue H, et al., Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11: 2597-605.
86. Zhao Q, Shen JH, Shen ZY, et al., Phosphorylation of fascin decreases the risk of poor survival in patients with esophageal squamous cell carcinoma. J Histochem Cytochem 2010; 58: 979-88.
87. Kim SJ, Kim DC, Kim MC, et al., Fascin expression is related to poor survival in gastric cancer. Pathol Int 2012; 62: 777-84.
88. Hashimoto Y, Shimada Y, Kawamura J, et al., The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 2004; 67: 262-70.
89. Li X, Zheng H, Hara T, et al., Aberrant expression of cortactin and fascin are effective markers for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Int J Oncol 2008; 33: 69-79.
90. Gu MJ, Kim JY, Park JB,. Fascin expression predicts lymph node metastasis and worse survival in small intestinal carcinoma. Pathology 2014; 46: 21-4.
91. Tsai WC, Jin JS, Chang WK, et al., Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters. J Histochem Cytochem 2007; 55: 955-62.
92. Lee TK, Poon RTP, Man K, et al., Fascin over-expression is associated with aggressiveness of oral squamous cell carcinoma. Cancer Lett 2007; 254: 308-15.
93. Chen SF, Yang SF, Li JW, et al., Expression of fascin in oral and oropharyngeal squamous cell carcinomas has prognostic significance - A tissue microarray study of 129 cases. Histopathology 2007; 51: 173-83.
94. Alam H, Bhate A, Gangadaran P, et al., Fascin overexpression promotes neoplastic progression in oral squamous cell carcinoma. BMC Cancer 2012; 12: 32.
95. Zou J, Yang H, Chen F, et al., Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. Eur J Cancer Prev 2010; 19: 11-7.
96. Gao W, Zhang C, Feng Y, et al., Fascin-1, ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma. PLoS One 2012; 7: e50710.
97. Durmaz A, Kurt B, Ongoru O, et al., Significance of fascin expression in laryngeal squamous cell carcinoma. J Laryngol Otol 2010; 124: 194-8.
98. Hanker LC, Karn T, Holtrich U, et al., Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer. Anticancer Res 2013; 33: 371-7.
99. Kostopoulou E, Daponte A, Terzis A, et al., Fascin in ovarian epithelial tumors. Histol Histopathol 2008; 23: 935-44.
100. Daponte A, Kostopoulou E, Papandreou CN, et al., Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer. Anticancer Res 2008; 28: 1905-10.
101. Kabukcuoglu S, Oner U, Ozalp SS, et al., The role of actin bundling protein fascin in the progression of ovarian neoplasms. Eur J Gynaecol Oncol 2006; 27: 171-6.
102. Cao D, Ji H, Ronnett BM,. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol 2005; 24: 67-72.
103. Wen YH, Yee H, Goswami S, et al., Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy. Int J Gynecol Pathol 2009; 28: 187-92.
104. Lin CK, Su HY, Tsai WC, et al., Association of cortactin, fascin-1 and epidermal growth factor receptor (EGFR) expression in ovarian carcinomas: correlation with clinicopathological parameters. Dis Markers 2008; 25: 17-26.
105. Nese N, Kandiloglu AR, Simsek G, et al., Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal Quant Cytol Histol 2010; 32: 90-101.
106. Darnel AD, Behmoaram E, Vollmer RT, et al., Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res 2009; 15: 1376-83.
107. Pelosi G, Pastorino U, Pasini F, et al., Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 2003; 88: 537-47.
108. Choi PJ, Yang DK, Son CH, et al., Fascin immunoreactivity for preoperatively predicting lymph node metastases in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Eur J Cardiothorac Surg 2006; 30: 538-42.
109. Teng Y, Xu S, Yue W, et al., Serological investigation of the clinical significance of fascin in non-small-cell lung cancer. Lung Cancer 2013; 82: 346-52.
110. Zhao J, Zhou Y, Zhang Z, et al., Upregulated fascin1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation. Cancer Lett 2010; 290: 238-47.
111. Pelosi G, Pasini F, Fraggetta F, et al., Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 2003; 42: 203-13.
112. Tan VY, Lewis SJ, Adams JC, et al., Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med 2013; 11: 52.
113. Yamakita Y, Matsumura F, Yamashiro S,. Fascin1 is dispensable for mouse development but is favorable for neonatal survival. Cell Motil Cytoskeleton 2009; 66: 524-34.
114. Yang S, Huang FK, Huang J, et al., Molecular mechanism of fascin function in filopodial formation. J Biol Chem 2013; 288: 274-84.
115. Jansen S, Collins A, Yang C, et al., Mechanism of actin filament bundling by fascin. J Biol Chem 2011; 286: 30087-96.
116. Van Audenhove I, Boucherie C, Pieters L, et al., Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization. FASEB J 2014; 28: 1805-18.
117. Chen L, Yang S, Jakoncic J, et al., Migrastatin analogues target fascin to block tumour metastasis. Nature 2010; 464: 1062-6.
118. Nagorny P, Krauss I, Njardarson JT, et al., Confirmation of the structures of synthetic derivatives of migrastatin in the light of recently disclosed crystallographically based claims. Tetrahedron Lett 2010; 51: 3873-5.